Form 4: DYAI CEO Mark Emalfarb Boosts Stake with RSU Vesting & Option Grant

Dyadic International CEO Mark Emalfarb acquired 102,609 shares of common stock from RSU vesting and received an annual grant of 126,000 stock options.

Summary

• CEO Mark Emalfarb acquired 102,609 shares of Dyadic International common stock on January 2, 2026.
• These shares were issued upon the full vesting of Restricted Stock Units (RSUs), which were granted as part of the key employee annual bonus for the year ended 2025, in lieu of a cash bonus.
• Following this transaction, Emalfarb directly beneficially owns 4,832,667 shares of common stock.
• Emalfarb also received an annual grant of 126,000 stock options on January 2, 2026, with an exercise price of $0.94.
• These stock options will vest in four equal installments, starting on the first anniversary of the grant date (January 2, 2027), subject to continued service.
• The options have an expiration date of January 2, 2036.

Sentiment

Score: 7

Explanation: The filing indicates routine executive compensation, including RSU vesting and an annual stock option grant, which are generally positive for aligning management incentives with shareholder interests. The CEO's increased direct ownership is a positive signal, though the filing itself is a standard disclosure of compensation rather than a strategic announcement.

Positives

• CEO Mark Emalfarb increased his direct beneficial ownership of common stock by 102,609 shares, demonstrating continued alignment with shareholder interests.
• The grant of 126,000 stock options further incentivizes the CEO's long-term performance and commitment to the company.
• The RSU vesting and option grant are part of the company's compensation structure, indicating a structured approach to executive incentives.

Future Outlook

The stock options granted to the CEO vest over four years, indicating a long-term incentive structure tied to future performance and continued service to the Issuer.

Management Comments

• Represents common stock issued upon the vesting of RSUs. The RSUs were granted pursuant to the Issuer's key employee annual bonus, in lieu of a cash bonus earned for the year ended 2025. The RSUs vested in full upon grant.
• Annual grant of stock options.
• This option vests in four equal installments beginning on the first anniversary of the date of grant, subject to continued service to the Issuer.

Industry Context

This Form 4 filing details an insider transaction, specifically equity compensation for the CEO. Such grants are common practice across industries to align executive incentives with long-term company performance and shareholder value. The specific terms (RSUs in lieu of cash bonus, multi-year option vesting) reflect a typical approach to executive compensation in the biotechnology or life sciences sector, where long-term development cycles are prevalent.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as a significant component of executive compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• Granting RSUs in lieu of a cash bonus for the prior year (2025) is a common strategy to conserve cash and further align executive interests with equity performance.
• The four-year vesting schedule for stock options is typical for long-term incentive plans, comparable to practices at companies like Regeneron Pharmaceuticals or Amgen, which also use multi-year vesting to encourage sustained performance and retention.
• The CEO's increased beneficial ownership of common stock (4,832,667 shares) is a substantial stake, often seen as a positive indicator of management's confidence, similar to high insider ownership observed in companies like Moderna or BioNTech during their growth phases.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's interests with shareholder value through increased equity ownership and long-term incentives.
• Employees: The RSU grant was part of a "key employee annual bonus," suggesting a broader compensation strategy that could impact other key employees.

Next Steps

• The granted stock options will begin to vest in four equal installments starting on January 2, 2027.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation, including RSU vesting and an annual stock option grant for the CEO. While the increased insider ownership is a positive signal of alignment, the filing itself does not contain new strategic or financial information that would warrant a change in investment thesis. It's a standard disclosure of compensation, suggesting a "hold" position is appropriate unless other fundamental factors change.

Keywords

Dyadic International, DYAI, Mark Emalfarb, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, CEO Compensation, Beneficial Ownership, Equity Grant